Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3477945 | Journal of Experimental & Clinical Medicine | 2012 | 7 Pages |
Abstract
New therapeutic targets are becoming increasingly popular for the treatment of a wide array of neurodegenerative diseases, the preferred targets being those that prevent neuronal apoptosis at multiple levels or those that can cross the blood-brain barrier in order to replace degenerated cells and promote neuronal regeneration. One such rapidly emerging neuroprotective agents is taurine. Taurine is a ubiquitous amino acid that satisfies most criteria to be classified as a neurotransmitter. Because of a wide spectrum of effects that taurine can induce on intrinsic apoptosis pathways, such as modulating mitochondrial pore permeability, attenuating endoplasmic reticulum stress, maintaining calcium homeostasis, and downregulating the activities of a range of pro-apoptotic proteins, including calpain and caspases, while upregulating a variety of anti-apoptotic proteins involved in glutamate and hypoxia-induced toxicity, taurine is being extensively studied and successfully applied for the treatment of neurodegenerative diseases. Another potential molecule being researched for combating neurodegenerative diseases is granulocyte colony-stimulating factor (G-CSF), which originates from the cytokine family of growth factors. G-CSF has gained widespread attention because of its ability to cross the blood-brain barrier, the presence of its receptors in the central nervous system, anti-apoptotic functions, and its proliferative role in the restoration of tissue survival via neurogenesis. In this review from the available current literature, the modes of action of taurine and G-CSF are discussed. Further mechanistic studies are warranted in order to fully realize the potential of these two molecules.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Chandana Buddhala, Howard Prentice, Jang-Yen Wu,